Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NVDQ's Cash to Debt is ranked higher than
93% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. NVDQ: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NVDQ' s 10-Year Cash to Debt Range
Min: 0.72  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.83
NVDQ's Equity to Asset is ranked higher than
83% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. NVDQ: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
NVDQ' s 10-Year Equity to Asset Range
Min: -0.16  Med: 0.75 Max: 0.97
Current: 0.83
-0.16
0.97
Interest Coverage No Debt
NVDQ's Interest Coverage is ranked higher than
87% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. NVDQ: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NVDQ' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 12.93
M-Score: 0.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -63.54
NVDQ's Operating margin (%) is ranked lower than
70% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. NVDQ: -63.54 )
Ranked among companies with meaningful Operating margin (%) only.
NVDQ' s 10-Year Operating margin (%) Range
Min: -1278.97  Med: -138.06 Max: -13.33
Current: -63.54
-1278.97
-13.33
Net-margin (%) -44.10
NVDQ's Net-margin (%) is ranked lower than
67% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. NVDQ: -44.10 )
Ranked among companies with meaningful Net-margin (%) only.
NVDQ' s 10-Year Net-margin (%) Range
Min: -1103.37  Med: -135.78 Max: -52.26
Current: -44.1
-1103.37
-52.26
ROE (%) -12.80
NVDQ's ROE (%) is ranked lower than
59% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. NVDQ: -12.80 )
Ranked among companies with meaningful ROE (%) only.
NVDQ' s 10-Year ROE (%) Range
Min: -522.61  Med: -54.08 Max: -15.03
Current: -12.8
-522.61
-15.03
ROA (%) -10.55
NVDQ's ROA (%) is ranked lower than
59% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. NVDQ: -10.55 )
Ranked among companies with meaningful ROA (%) only.
NVDQ' s 10-Year ROA (%) Range
Min: -95.19  Med: -45.04 Max: -12.37
Current: -10.55
-95.19
-12.37
ROC (Joel Greenblatt) (%) -79.75
NVDQ's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. NVDQ: -79.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVDQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3434.48  Med: -468.10 Max: -107.51
Current: -79.75
-3434.48
-107.51
Revenue Growth (3Y)(%) 24.70
NVDQ's Revenue Growth (3Y)(%) is ranked higher than
91% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. NVDQ: 24.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVDQ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.9  Med: 22.20 Max: 149.3
Current: 24.7
-6.9
149.3
EBITDA Growth (3Y)(%) 17.60
NVDQ's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. NVDQ: 17.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVDQ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.7  Med: -3.40 Max: 67.7
Current: 17.6
-30.7
67.7
EPS Growth (3Y)(%) 15.70
NVDQ's EPS Growth (3Y)(%) is ranked higher than
77% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. NVDQ: 15.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVDQ' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.9  Med: 1.40 Max: 64.2
Current: 15.7
-26.9
64.2
» NVDQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

NVDQ Guru Trades in Q3 2014

Steven Cohen 130,400 sh (New)
Ron Baron 47,400 sh (+912.82%)
Chuck Royce 60,000 sh (unchged)
» More
Q4 2014

NVDQ Guru Trades in Q4 2014

PRIMECAP Management 760,082 sh (New)
Chuck Royce 77,700 sh (+29.50%)
Ron Baron 57,600 sh (+21.52%)
Steven Cohen Sold Out
» More
Q1 2015

NVDQ Guru Trades in Q1 2015

Jim Simons 25,600 sh (New)
PRIMECAP Management 1,085,082 sh (+42.76%)
Ron Baron 57,600 sh (unchged)
Chuck Royce 77,700 sh (unchged)
» More
2015

NVDQ Guru Trades in 2015

PRIMECAP Management 3,853,182 sh (+255.11%)
» More
» Details

Insider Trades

Latest Guru Trades with NVDQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 116.28
NVDQ's Forward P/E is ranked lower than
91% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. NVDQ: 116.28 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.59
NVDQ's P/B is ranked lower than
62% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. NVDQ: 4.59 )
Ranked among companies with meaningful P/B only.
NVDQ' s 10-Year P/B Range
Min: 0.91  Med: 5.70 Max: 274
Current: 4.59
0.91
274
P/S 16.61
NVDQ's P/S is ranked lower than
85% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. NVDQ: 16.61 )
Ranked among companies with meaningful P/S only.
NVDQ' s 10-Year P/S Range
Min: 1.67  Med: 13.70 Max: 327.33
Current: 16.61
1.67
327.33
Current Ratio 18.43
NVDQ's Current Ratio is ranked higher than
98% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. NVDQ: 18.43 )
Ranked among companies with meaningful Current Ratio only.
NVDQ' s 10-Year Current Ratio Range
Min: 1  Med: 4.42 Max: 26.52
Current: 18.43
1
26.52
Quick Ratio 17.59
NVDQ's Quick Ratio is ranked higher than
97% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. NVDQ: 17.59 )
Ranked among companies with meaningful Quick Ratio only.
NVDQ' s 10-Year Quick Ratio Range
Min: 0.85  Med: 4.11 Max: 26.46
Current: 17.59
0.85
26.46
Days Inventory 125.58
NVDQ's Days Inventory is ranked lower than
73% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. NVDQ: 125.58 )
Ranked among companies with meaningful Days Inventory only.
NVDQ' s 10-Year Days Inventory Range
Min: 53.17  Med: 80.39 Max: 310.38
Current: 125.58
53.17
310.38
Days Sales Outstanding 124.64
NVDQ's Days Sales Outstanding is ranked lower than
87% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. NVDQ: 124.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVDQ' s 10-Year Days Sales Outstanding Range
Min: 37.76  Med: 88.61 Max: 344.72
Current: 124.64
37.76
344.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.20
NVDQ's Price/Net Cash is ranked higher than
59% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.89 vs. NVDQ: 7.20 )
Ranked among companies with meaningful Price/Net Cash only.
NVDQ' s 10-Year Price/Net Cash Range
Min: 5.37  Med: 8.96 Max: 63.75
Current: 7.2
5.37
63.75
Price/Net Current Asset Value 5.80
NVDQ's Price/Net Current Asset Value is ranked higher than
64% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.30 vs. NVDQ: 5.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVDQ' s 10-Year Price/Net Current Asset Value Range
Min: 4.31  Med: 7.37 Max: 88.33
Current: 5.8
4.31
88.33
Price/Tangible Book 5.23
NVDQ's Price/Tangible Book is ranked higher than
51% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.26 vs. NVDQ: 5.23 )
Ranked among companies with meaningful Price/Tangible Book only.
NVDQ' s 10-Year Price/Tangible Book Range
Min: 2.6  Med: 6.53 Max: 455
Current: 5.23
2.6
455
Price/Median PS Value 1.21
NVDQ's Price/Median PS Value is ranked lower than
59% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. NVDQ: 1.21 )
Ranked among companies with meaningful Price/Median PS Value only.
NVDQ' s 10-Year Price/Median PS Value Range
Min: 0.15  Med: 0.99 Max: 23.17
Current: 1.21
0.15
23.17
Earnings Yield (Greenblatt) (%) -3.20
NVDQ's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NVDQ: -3.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVDQ' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -7  Med: 0.00 Max: 0
Current: -3.2
-7
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:NDQ.Canada, NQT.Germany,
Novadaq Technologies Inc was incorporated under the Canada Business Corporations Act on April 14, 2000. The Company develops and commercializes medical imaging and therapeutic devices for use in the operating room. It's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company's business activities are conducted through one segment, which consists of medical devices. Its product includes, SPY Elite, PINPOINT Endoscopic Fluorescence Imaging, FIREFLY System for Robotic Surgery, LUNA Fluorescence Angiography and CO2 HEART LASER System. The SPY Imaging System provides clinically relevant information that empowers surgeons to make informed critical decisions in the operating room. PINPOINT Endoscopic Fluorescence Imaging System combines all of the fluorescence imaging capabilities of SPY Imaging with the HD visible light imaging capabilities of a traditional endoscopic imaging system. FIREFLY system enables surgeons performing robotic surgery to benefit from fluorescence imaging, with initial use in applications ranging from urology to gynecology. LUNA fluorescence angiography enables clinicians to visually assess tissue perfusion in diabetic foot ulcers and non-healing wounds. The CO2 HEART LASER System consists of: the CO2 HEART LASER mobile console and the CO2 HEART LASER disposable hand pieces. The Company's intellectual property consists of 49 patent families representing 128 granted or allowed patents and 90 pending applications in various stages of review and prosecution.
» More Articles for NVDQ

Headlines

Articles On GuruFocus.com
Prem Watsa Increases NYT and Two Others May 15 2013 
comment on NVDQ Mar 03 2013 
Prem Watsa Increases Novadaq Technologies Ownership to 6.6 Pct Feb 14 2013 

More From Other Websites
5 Hated Earnings Stocks You Should Love Jul 27 2015
NOVADAQ TECHNOLOGIES INC Financials Jul 16 2015
NOVADAQ to Release Second Quarter 2015 Financial Results on July 28, 2015 – Conference Call to... Jul 14 2015
NOVADAQ to Release Second Quarter 2015 Financial Results on July 28, 2015 -- Conference Call to... Jul 14 2015
NOVADAQ to Present at the 35th Annual William Blair Stock Conference Jun 04 2015
NOVADAQ to Present at the 35th Annual William Blair Stock Conference Jun 04 2015
NOVADAQ REPORTS VOTING RESULTS FROM ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS May 14 2015
NOVADAQ Reports Voting Results From Annual and Special Meeting of Shareholders May 14 2015
NOVADAQ To Participate in May Investor Conferences Apr 30 2015
NOVADAQ to Participate in May Investor Conferences Apr 30 2015
Nasdaq stocks posting largest percentage decreases Apr 29 2015
Nasdaq stocks posting largest percentage decreases Apr 29 2015
Novadaq reports 1Q loss Apr 28 2015
Novadaq reports 1Q loss Apr 28 2015
NOVADAQ Reports First Quarter 2015 Financial Results Apr 28 2015
NOVADAQ Reports First Quarter 2015 Financial Results Apr 28 2015
Novadaq to Host First Quarter 2015 Earnings Conference Call and Webcast Live on Tuesday, April 28,... Apr 27 2015
NOVADAQ to Release First Quarter 2015 Financial Results on April 28, 2015 – Conference Call to... Apr 15 2015
NOVADAQ To Participate in Upcoming Investor Conferences Mar 23 2015
NOVADAQ Announces Appointment of Patrice E. Merrin to Its Board of Directors Mar 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK